Increased autophagy blocks HER2-mediated breast tumorigenesis

Area of Science:

• Molecular Biology
• Oncology
• Cellular Biology

Background:

• Loss of the autophagy gene beclin 1 (BECN1) is associated with increased risk of aggressive breast cancers, including human epidermal growth factor receptor 2 (HER2)-positive types.
• The role of autophagy induction in preventing HER2-positive breast tumor growth remains unclear.

Purpose of the Study:

• To investigate how HER2 regulates autophagy in breast cancer cells.
• To evaluate the efficacy of genetic and pharmacological strategies for increasing autophagy in inhibiting HER2-driven breast cancer growth.

Main Methods:

• In vitro studies on the interaction between HER2 and Beclin 1 in breast cancer cells.
• In vivo studies using genetically engineered mice with increased basal autophagy (Becn1 mutation) and human breast cancer xenografts.
• Treatment with a Tat-Beclin 1 autophagy-inducing peptide and a HER2 tyrosine kinase inhibitor (TKI).

Main Results:

• HER2 interacts with Beclin 1, inhibiting autophagy in breast cancer cells.
• Mice with increased basal autophagy were protected from HER2-driven mammary tumors, with HER2 unable to inhibit autophagy.
• Tat-Beclin 1 peptide treatment effectively inhibited tumor growth in HER2-positive xenografts, comparable to a HER2 TKI, by inducing autophagy and disrupting HER2/Beclin 1 binding.

Conclusions:

• HER2-mediated inhibition of Beclin 1 and autophagy contributes to HER2-driven tumorigenesis.
• Strategies targeting HER2/Beclin 1 binding or enhancing autophagy represent a potential novel therapeutic avenue for HER2-positive breast cancer.